CHEPLAPHARM Arzneimittel GmbH

Your contact persons

Stephanie Lemke

Senior Investor Relations Manager

Jens Remmers

Head of Treasury & Investor Relations

ESG Ratings & Downloads

ESG Ratings

ESG rating agencies make an independent assessment of our ESG profile. Since 2020, the ESG rating agency Sustainalytics has been evaluating CHEPLAPHARM's ESG information. Sustainalytics uses a rating system on a scale of 0 to 50, where a lower score means a better ESG risk rating.

At the end of 2021, CHEPLAPHARM received an ESG rating update with an "ESG Risk Rating" of 28.6 ("medium risk"). Within one year, CHEPLAPHARM, rated as "severe risk" in 2020, was able to improve by 13.7 points as a result of its increased ESG transparency. Compared to the entire sector "Pharmaceuticals", CHEPLAPHARM ranks among the top 20% of all companies.

Get to know more about ESG at Cheplapharm.

More information on ESG topics and how Cheplapharm deals with them can be found in the following documents for download:

Investor Relations entdecken

Weitere ESG-Themenbereiche

Back to top expand_less